Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended					1 Months Ended	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Mar. 31, 2013 Equity securities [Member] entity	Dec. 31, 2012 Equity securities [Member] investment	Dec. 31, 2012 Voltaren Gel [Member]	Mar. 31, 2013 Voltaren Gel [Member]	Mar. 31, 2013 Qualitest [Member]	Dec. 31, 2012 Qualitest [Member]	Mar. 31, 2013 Maximum [Member] Qualitest [Member]	Mar. 31, 2013 Minimum [Member] Qualitest [Member]	Mar. 31, 2013 Prepaid expenses and other current assets [Member]	Mar. 31, 2013 Accrued Expenses [Member]	Dec. 31, 2012 Less than twelve months [Member] Equity securities [Member] securities	Mar. 31, 2013 More than twelve months [Member] Equity securities [Member] securities	Dec. 31, 2012 More than twelve months [Member] Equity securities [Member] securities	Mar. 31, 2013 1.75% Convertible Senior Subordinated Notes Due 2015 [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Interest Rate																	1.75%
Stock price volatility	32.00%	32.00%
Foreign currency derivative assets at fair value												$ 100,000
Fair Value of foreign exchange forward contracts, liabilities													200,000
License agreement term extension							1 year
Royalty guarantees, commitments, amount						21,300,000
Gross unrealized losses	793,000	(206,000)
Contingent cash consideration agreement	1,194,000		6,195,000							7,500,000	0
Basis points								3.00%
Acquisition related contingent consideration fair value	1,194,000		6,195,000					4,000,000	8,900,000
Number of securities in an unrealized loss position														1	1	1
Number of investment in publically traded companies				3	3
Asset impairment charges	1,100,000	40,000,000
Other Payments to Acquire Businesses								$ (5,000,000)